Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their ...

Matthew Macfadyen and Keira Knightley as Darcy and Elizabeth Bennett in the 2005 screen adaptation of Pride and Prejudice. FilmAffinity At the beginning of Pride and Prejudice, Jane Austen’s most well ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. For decades, the federal government has supported the infrastructure that makes ...

Federal agencies have proposed sharp limits on how much universities can recover in indirect costs for federally funded research — a move that could cost Duke more than $200 million annually and has ...

A federal judge tossed out the National Science Foundation’s policy capping reimbursements for costs indirectly related to research, finding “severe” deficiencies in the agency’s reasoning for the ...

A federal judge has blocked the Trump administration from implementing a 15% cap on indirect research costs funded by NSF. A federal judge has granted summary judgment in favor of several universities ...

Soon to be the official tool for managing Python installations on Windows, the new Python Installation Manager picks up where the ‘py’ launcher left off. Python is a first-class citizen on Microsoft ...

June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...

Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...